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EYERICH ET AL 37integration of ‘‘omics’’ data sets, and development of predictive
computational models. Although no one individual model
recapitulates the complex AD pathophysiology, our review
highlights insights gained into key elements of cutaneous
biology, molecular pathways, and therapeutic target
identification through each approach. Recent developments in
computational analysis, including application of machine
learning and a systems approach to data integration and
predictive modeling, highlight the applicability of these methods
to AD subclassification (endotyping), therapy development, and
precision medicine. Such predictive modeling will highlight
knowledge gaps, further inform refinement of biological models,
and support new experimental and systems approaches to AD.
(J Allergy Clin Immunol 2019;143:36-45.)
Key words: Atopic dermatitis, atopic eczema, endotype, human
models, machine learning, mechanistic models, precision medicine,
tissue culture models, skin equivalents, systems biology
Atopic dermatitis (AD; synonym atopic eczema) has a complex
etiology involving multiple genetic and environmental factors.1,2
With its very high incidence in childhood, chronicity, devastating
effect on quality of life for affected patients and their families,
enormous socioeconomic costs, and limited therapeutic options
to date, AD represents a major challenge. Furthermore, there is
clear evidence that AD represents a systemic inflammatory
disease with multiple comorbidities extending beyond the
well-recognized atopic associations.3 Consequently, a number of
animal models have been developed and used by investigators
and the pharmaceutical industry to better understand the disease
and consider new pathways to target.4 However, as recently
reviewed, mouse models do not adequately reflect the
transcriptomic and gene pathways activated in human AD skin,5
and the intrinsic difference between mouse and human skin
represents a barrier to direct translation of findings from animals
into human disease. Consequently, there has been increasing
interest in experimental studies in human subjects (in part
facilitated by technological and ‘‘omics’’ developments), cell
culture models using human tissue, and use of computational or
mathematical models that are developed by integrating these data.
In this review article we have used the term human ADmodel to
define representations of the disease state and interventions that
enable scientific insight into disease pathogenesis, disease course,
and response to therapy.We delineate and critically appraise these
AD modeling approaches that range from experimental study of
human skin in vivo (including challenge studies and detailed
phenotyping and investigation of patients harboring specific
genetic mutations) to generation of AD-relevant models by using
immunologic, genetic, and molecular methods in 2-dimensional
and 3-dimensional human tissue culture to development of
in silico computational models using a systems biology approach.
Although by definition a reductionist approach cannot
recapitulate the full spectrum of AD, these models have greatly
increased our understanding of the molecular drivers of AD and
provide a powerful tool for preclinical drug development and
target validation. However, just as the etiology, clinical
expression, and severity of AD range broadly among patients,
in vitro and in silico models of AD vary widely both in how the
AD phenotype is induced and how the models are evaluated.
Therefore we invited members of the International Eczema
Council (www.eczemacouncil.org), a group of experts in AD,and associated authorities in the field to contribute to a scoping
and development meeting and subsequently to evaluate and
critically appraise the breadth of human AD and computational
models to determine their strengths and weaknesses in how they
recapitulate the pathophysiology of AD and enable therapeutics
to be tested and validated.IN VIVO MODELS OF AD
Two general approaches using human in vivomodels have been
followed to dissect the pathogenesis of AD: (1) the study of rare
genetic variants with AD-like phenotypes and (2) the
experimental challenge of patients with or without AD with
allergens or irritants. Regarding the first approach, numerous
studies have characterized genetic disorders that display skin
barrier function abnormalities. Most often, these studies
characterized ichthyosis vulgaris, a disease that allowed insight
into the function of the epidermal differentiation gene filaggrin
(FLG), in which mutations show the strongest association to
AD development of all known genes (Fig 1).6
Other studies have focused on disorders characterized by
systemic inflammation3 and immunodeficiency with AD-like
skin manifestations (Fig 1). One example is immunodysregula-
tion, polyendocrinopathy, enteropathy, X-linked syndrome, which
serves as a model to study how systemic imbalances in the regula-
tory T-cell population can drive cutaneous AD-like inflammation.7
In addition, the link between type 2 immunity; transcription
factors, such as Janus kinase or signal transducer and activator
of transcription; and high levels of IgE was investigated in
immunodeficiency syndromes, such as signal transducer and
activator of transcription 3 and dedicator of cytokinesis 8 hyper-
IgE syndromes or combined immunodeficiency disorders.8,9
Table E1 in this article’s Online Repository at www.jacionline.
org lists the main genetic conditions that have provided insight
into AD pathogenesis to date. Although the study of rare variants
offers the opportunity to delineate distinct molecular mechanisms
and control pathways of a particular phenotype and thus can be
regarded as ‘‘human models of AD,’’ a limitation of this approach
is that not all observed phenomena are relevant in patients with
AD, which is more complex and heterogeneous than monogenic
disorders.
The second in vivo approach to study the pathogenesis of AD is
standardized challenge with allergens or other environmental
factors. The most commonly used model is the atopy patch test
(APT), an epicutaneous challenge of specific allergens dissolved
in vehicle,10 which has provided insight into the temporal
development of immune phenomena in patients with AD (see
Table E2 in this article’s Online Repository at www.jacionline.
org).11 Although developed in part to define clinically relevant
reactions to aeroallergens, food allergens, and autoantigens,12-14
its validity and predictive value depend on a variety of factors
FIG 1. Diagrammatic representation of ‘‘human knockout’’ monogenic models, providing insight into the
pathomechanisms of AD. Specific genetic variants affecting the structural and/or immune functions of skin or
other organs recapitulate features but not the entire phenotype of atopic inflammation and AD. CARD11,
Caspase recruitment domain-containing protein 11; CDSN, corneodesmosin; CTLA4, cytotoxic T lymphocyte–
associated protein 4;DOCK8, dedicator of cytokinesis 8;DSG1, desmoglein 1;DSP, desmoplakin; FLG, filaggrin;
FOXP3, forkhead box protein 3; IL2RA, IL-2 receptor a; IL4RA, IL-4 receptor a; IFNGR1, IFN-g receptor 1;MALT1,
mucosa-associated lymphoid tissue lymphoma translocation protein 1; PGM3, phosphoglucomutase 3; RAG1,
Recombination-activating gene 1; RAG2, recombination-activating gene 2; SPINK5, serine protease inhibitor
Kazal type 5; STAT3, signal transducer and activator of transcription 3.
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practice. Experimentally, the APT has provided insight into the
temporal sequence of cutaneous cellular infiltrates. Acute skin
lesions show a highly reproducible TH2-dominant inflitrate,
16
although other cell types, including TH17 cells, are also
present.17,18 This TH2 dominance is in sharp contrast to other
inflammatory skin diseases, such as psoriasis.19,20 Time-course
studies have shown that additional immune cell subsets, such as
TH1 and TH22 cells, progressively infiltrate the skin during an
ongoing APT reaction, mirroring the cellular composition of
acute versus chronic human AD.17,21 The APT has also been
used to characterize dendritic cells within early lesional AD
skin, such as inflammatory dendritic epidermal cells.18
Furthermore, the APT has provided insight into the interaction
of microbiota and our immune system, in particular the role of
bacteria-derived superantigens acting as an amplifier of the
allergen-specific cutaneous response in patients with AD.21-23
In all these experimental APT studies, the population of patients
with AD were well defined, with specific inclusion and exclusion
criteria (although the precise definitions of AD varied); in most
studies AD, together with specific IgE to the corresponding
allergen used in the APT, was an inclusion criterion.
Hapten challenge to induce classical allergic contact dermatitis
(ACD) in patients with AD has also broadened our understanding
of AD pathogenesis (see Table E2). Whether patients with AD
have an increased risk of ACD remains controversial and might
depend on whether they harbor FLG mutations, which might
have allowed increased allergen penetration. However, attenuated
ACD reactions have been reported in patients with AD compared
with control subjects in a severity-dependent manner.24,25 This
might be due to the fact that haptens induce distinct immune
responses,26 with fragrances mimicking the TH2/TH22
dominance of AD, whereas nickel, 2,4-Dinitrochlorobenzene(DNCB), or imiquimod27 induced TH1/TH17-skewed immune re-
sponses. Of note, patients with AD show a TH2-skewed ACD re-
action,28 and this immune deviation might account for the
diminished ACD prevalence in patients with AD. ATH2 immune
reaction profile of patients with AD was also observed in an aero-
challenge setup,29 as well as when challenging patients with AD
with physical factors, such as hard water.30,31
All current challenge models have some limitations (see Table
E2) because they only represent acute reactions, and the small
areas of application cannot reproduce the intense pruritus and
sleep disturbances usually present in patients with AD.
Furthermore, to date, they have not stratified for genetic
differences/endotypes among patients with AD. For example,
comparing APTs in patients with and without FLG mutations
might be a useful line of future investigation. Moreover, in the
future, molecular profiling of lesional skin from standardized
challenge models adjusted according to AD endotype can be
used in early clinical studies to evaluate the potential of new drugs
to improve AD.32IN VITRO MODELS
As shown in Table E3 in this article’s Online Repository at
www.jacionline.org, there are several 2-dimensional cell-culture
and 3-dimensional organotypic models for AD that complement
each other in addressing specific experimental questions.
Although 2-dimensional cell culture models (by definition) do
not duplicate the architecture of skin, they are amenable to
high-throughput techniques for drug discovery and target
validation (2-dimensional model section, see Table E3).
Accordingly, Otsuka et al33 used 2-dimensional cultures to screen
a chemical library for compounds that enhance FLG
transcriptional activation and mRNA expression, suggesting a
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FIG 2. Human in vitro models of AD. In vitro models can be designed to address specific experimental
questions based on the input materials of the cultures. Assessment of the cultures or output depends on
the type of culture. CDSN, Corneodesmosin; DSG1, desmoglein 1; FLG, filaggrin; HEE, human epidermal
equivalent; HSE, human skin equivalent (inset, fibroblasts in collagen); IVL, involucrin; KRT10, keratin 10;
shRNA, short hairpin RNA; siRNA, small interfering RNA; TEER, transepithelial electrical resistance;
TSLP, thymic stromal lymphopoietin.
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3-dimensional models replicate the stratified squamous
epithelium of epidermis but require specific expertise and are
time consuming. Epidermal equivalents consist of keratinocytes
without a dermal compartment, whereas skin equivalents have a
dermis, such as fibroblast-embedded collagen (3-dimensional
model section, see Table E3). Both 2-dimensional and
3-dimensional models are amenable to treatment with
disease-relevant cytokines, gene knockdown, use of
patient-derived cells, and/or coculture (Fig 2 and see Table E3).
The immune system is a major driver of AD, and in vitro
immune modulation with disease-relevant cytokines, such as
interleukins, can lead to AD-like phenotypes in normal primary
keratinocytes34 and 3-dimensional models (3-dimensional
cytokine model section, see Table E3).35-41 Knockdown of
filaggrin (FLG) in culture systems can provide insight into the
molecular and proteomic changes associated with its loss in
patients with AD,42 and combining FLG knockdown with other
perturbations, such as cytokine treatment, can be used to study
the multifactorial drivers of AD. For example, Honzke et al43
reported that FLG knockdown exacerbated epidermal responses
to IL-4 and IL-13, including increased proliferation and
keratinocyte-released cytokines in 3-dimensional skin
equivalents. Patient-derived cells for 2-dimensional and
3-dimensional culture or tissue for explant culture are limited
by access and availability but might be the most relevant in terms
of modeling AD.44-47
Furthermore, patients’ biopsy specimens can be a source of
skin cells other than keratinocytes, allowing for coculture models.
Given that multiple systems contribute to AD, coculture models
that include immune cells, dermal fibroblasts, and neurons canbegin to address their interplay with keratinocytes. For example,
Berroth et al47 derived keratinocytes and fibroblasts from normal
andAD skin and showed that AD-derived fibroblasts are sufficient
to decrease FLG mRNA in normal-derived keratinocytes in
3-dimensional culture. Moreover, combining FLG knockdown
with CD41 activated T cells uncovered direct cross-talk between
keratinocytes and T cells that resulted in T-cell migration within
the dermal compartment toward the epidermis.48
These studies highlight the levels of complexity that can be
engineered into the 3-dimensional culture models.
Three-dimensional culture systems have also been used to
understand environmental influences on skin, including air
pollution, UV radiation exposure, and bacterial infection.49-51
Therefore these relevant environmental factors could be
incorporated into in vitro models of AD. The 3-dimensional
cultures and skin explants can also be used to assess the
comparative efficacy and practical applicability of novel drug
delivery systems.52,53 Notably, despite the assorted
methodologies applied in developing in vitromodels of AD, there
is overlap in the AD-like characteristics among the various
models: most produce perturbed epidermal morphology,
abnormal differentiation, and barrier dysfunction. Most often,
disparities in reported phenotypes appear to stem, at least in
part, from differences in the methodologies used in evaluating
models (not necessarily because of the absence of the phenotype).
Although in vitromodels might not mimic certain symptomatic
and/or subjective aspects of the disease, such as pruritus and pain,
they allow monitoring of changes in epidermal morphology and
differentiation, gene and protein expression, lipid synthesis, and
barrier function. Histologically, AD skin sections and most
3-dimensional models of AD show profound changes in the
J ALLERGY CLIN IMMUNOL
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and increased cellularity because of hyperproliferation
(3-dimensional model section, see Table E3). Changes in
expression of genes (detected by using microarray,
RNA-sequencing, or quantitative PCR) and protein (detected by
using liquid chromatography–mass spectrometry, Western
blotting, ELISA, or immunohistochemistry) can be used to
evaluate disturbances in differentiation and immune response in
2-dimensional and 3-dimensional models. Lipid synthesis, which
is required for optimal barrier function, can be monitored by
expression of related enzymes or directly by using mass
spectrometry. Epidermal barrier function can be monitored in
2-dimensional and 3-dimensional models, depending on the
assay.
We recommend that the phenotype of any AD in vitro model
should be extensively characterized and should include parallel
analysis of epidermal morphology, differentiation status, loss or
gain of key transcripts/proteins, analysis of immune components,
and assessment of functional epidermal barrier parameters. Full
characterization of any AD model can inform downstream
evaluation of potential therapeutic agents with respect to
reversing different aspects of the disease. Testing potential targets
or drugs in several model types can add rigor and indicatewhether
a signaling pathway or protein is central to the diverse
manifestations of AD.IN SILICO COMPUTATIONAL MODELS
A core element of a systems biology approach is development
of in silico computational models (mechanistic models) by means
of integration of different types of experimental and clinical data
from multiple studies, including those associated with disease
conditions. In silico experiments (ie, computer simulations or
mathematical analysis of in silico models) can test
model-specific hypotheses, predict disease prognosis or treatment
outcomes, and identify knowledge gaps, guiding future
experiments and clinical trials that produce further data. This
iterative process refines in silico models, providing holistic
systems-level mechanistic insight into how perturbations
(treatments or risk factors) lead to whole-organism phenotypes.
A mechanistic model describes causative interactions between
the system’s components involved in the phenomena of interest
(eg, disease or treatment outcomes). Existing mechanistic models
of AD vary widely, depending on the levels of interaction (tissue,
cells, proteins, and genes) included in the model and
mathematical methods used to describe the interactions.
Domınguez-H€uttinger et al54 developed a multi-scale
deterministic model that delineates interactions between the
environment, skin barrier integrity, and immune activation using
ordinary differential equations (Table I).54-61 Two bistable
‘‘switches’’ are described: the first regulating the onset of AD
flares and the second controlling progression to severe and
persistent disease. The model predicts, for example, that
genetic predisposition to barrier dysfunction (eg, FLG
haploinsufficiency) predisposes to longer flares and more
persistent disease and that prophylactic emollient use might be
beneficial (Table I).
Application of optimal control theory to the hybrid
mathematical model can inform the design of patient-specific
optimal strategies for ‘‘proactive therapy’’ to prevent recurrent
flares once the disease has been brought under initial control.55For example, this computational model supports the need for a
greater topical steroid treatment dose after disease worsening
and the potential need for more frequent than 2 to 3 days per
week application of topical steroid treatment to maintain
remission62 in patients with FLG haploinsufficiency (Table I),
presenting a readily testable stratification treatment regimen
based on genotype.
Polak et al56 developed a stochastic Petri net model that
delineates genetic regulatory mechanisms responsible for
immune responses in Langerhans cells (LCs; Table I). The model
describes reported interactions between interferon regulatory
factors, interferon regulatory factor transcription partners, and
DNA sequences in a logic-based diagram. In vitro experiments
validated model predictions that the ability of LCs to present a
peptide is altered by cytokine milieu and that a phosphoinositide
3-kinase g inhibitor reduces the ability of LCs to induce TH1
responses. These smaller-scale and focused mechanistic models
can describe detailed interactions that are difficult to include
and validate in multiscale models. Inclusion of the detailed
interactions would make the multiscale models too complex to
interpret and validate because of the current lack of quantitative
dynamic data measuring the variables across different scales
simultaneously.
Subramanian et al57 used a pathway model that included
manually curated skin-specific pathways and relevant genes
(Table I). Pathway enrichment analysis using transcriptomic
data sets of patients with AD provided mechanistic insights into
drug actions of topical betamethasone and pimecrolimus. The
pathway model would allow in silico experiments once the
kinetics parameters for pathways are identified to provide
quantitative and dynamic predictions of disease progression and
treatment outcomes.
Population pharmacokinetic and pharmacodynamic models
have also been developed to describe differences and variability
in pharmacologic effects observed in large clinical studies for AD
treatment.58,59 The authors identified the model parameters that
best fit the effects of nemolizumab and dupilumab measured in
terms of AD severity score or pharmacokinetics (Table I).58,59
Population pharmacokinetic and pharmacodynamicmodels could
help achieve mechanistic understanding of pharmacologic effects
if combined with mechanistic models.
One of the challenges in developing mechanistic models is
identification of the components and pathways relevant to the
model-specific hypothesis to be tested. This can be achieved by
using unbiased multivariate analyses of a collection of large-scale
data, for example by using machine learning data analysis.
Application of machine learning methods to AD-related data is
relatively limited at present, but some relevant works have been
already published. Thijs et al60 developed a piecewise linear
mixed model to predict AD severity scores after different
treatments, and Kiiski et al61 developed a multivariate logistic
regression model to predict a ‘‘good treatment response.’’
A sufficient level of cross-validation is crucial to reduce bias
and ensure the general applicability of models with predictive
power beyond mere data description.
All the models presented above were developed based on the
published data derived from studies in which the inclusion and
exclusion criteria for ADwere specified. Although the majority of
studies used the Hanifin and Rajka criteria and specified further
clinical (including comorbidities) and demographic details, it is
clear that patients with AD present with a wide spectrum of
TABLE I. In silico computational models of AD
Model type Scientific merits Clinical utility Limitations Key features
Key findings/
predictions References
Multiscale
mechanistic
model
Mechanistic
understanding of
system-level
effects of
potential triggers
and processes on
disease state
Identification of
therapeutic
targets and their
mechanisms for
further clinical
investigation
Prediction of
dynamic effects
of therapeutics,
leading to patient
stratification
Models developed
based on
hypothesized
relationships that
were previously
described
experimentally
A hybrid ordinary
differential
equation model
of the dynamic
interplay
between skin
barrier function,
immune
responses, and
environmental
stressors that
determines AD
pathogenesis
A hybrid model of
treatment effects
of corticosteroids
and emollients on
AD pathogenesis
and exploration
of optimal
regimens for
induction of
remission and
maintenance of
remission
Preventive effects
of emollients
against AD
progression
(shown by
clinical trials)
Synergistic effects
of environmental
(eg, microbiome)
and genetic (eg,
FLG) risk factors
on AD
progression
(shown by mouse
experiments with
ovalbumin
challenge or
dose-dependent
effects of FLG
deficiency)
Poor adherence to
the suggested
optimal treatment
schedule leads to
higher treatment
doses.
Application of
corticosteroids
for 2 consecutive
days per week is
optimal for the
maintenance
period.
Dominguez-
Huttinger et al54
Christodoulides
et al55
Gene regulatory
network model
Understanding of
gene regulatory
mechanisms
behind disease
processes
Identification of
therapeutic
targets and their
mechanisms at
the gene
regulation level
Models developed
based on
published genetic
interactions
Stochastic Petri net
model of
interferon
regulatory factor
gene regulatory
network in
response to
in vitro treatment
of LCs with
TNF-a and TSLP
In vitro experiments
validated
predictions that
the ability of LCs
to present a
peptide is altered
by cytokine
milieu and that
PI3Kg inhibitor
reduces the
ability of LCs to
induce TH1
responses.
Polak et al56
Pathway models Understanding of
disease
mechanisms
Identification of
therapeutic
targets and their
mechanisms
Models developed
based on
published
pathways
A pathway model
including 35
manually curated
skin-specific
pathways and
>2600 genes
Pathway
enrichment
analysis using
transcriptomic
data sets of 10
patients with AD
treated with
betamethasone
valerate and
pimecrolimus
predicted
mechanism of
action of both
drugs on human
skin.
Subramanian et al57
(Continued)
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TABLE I. (Continued)
Model type Scientific merits Clinical utility Limitations Key features
Key findings/
predictions References
Population PK/PD
models
Understanding of
differences and
variability in
pharmacologic
effects among a
target population
from clinical trial
data
Prediction of
optimal dose
regimen
Testing effects of
weight, sex, etc
Requires large
clinical data to
have sufficient
predictive power
PK/PD model for
serum
nemolizumab
and pruritus VAS
developed from
299 patients’
time course data
Two-compartment
PK model for
dupilumab
developed from
data of 197
healthy
volunteers and
patients with AD
from 6 studies
An appropriate flat
dose regimen that
is independent of
body weights is
used.
Production rate of
IL-4Ra is similar
for patients with
AD and healthy
volunteers and
does not change
over time.
Saito et al58
Kovalenko et al59
Machine learning
predictive models
Unbiased analyses
of differences
between disease
and nondisease
(including
treated) tissue/
patients and
prediction of
clinical outcomes
(prognostic and
therapeutic)
Identification of
disease and
therapeutic
targets
Findings can feed
into mechanistic
models
Causative
mechanisms
remain largely
unknown
Machine learning
applications to
atopic eczema
relatively limited
at present
Piecewise linear
mixed models to
predict EASI
scores at 3 future
time points from
baseline
biomarkers
Developed from
data of 150
serum
biomarkers
measured in 193
patients with AD
Multivariate logistic
regression model
to identify
predictors of
long-term
response to
topical
maintenance
treatment in AD
on 169 patients
Combination of
TARC, IL-22,
and sIL-2R
provides a good
predictor for
future EASI
score.
Serum total IgE
(rather than the
initial severity) is
the most
important factor
predicting a good
long-term
treatment
outcome.
Thijs et al60
Kiiski et al61
EASI, Eczema Area and Severity Index; IL-4Ra, IL-4 receptor antagonist; PI3Kg, phosphoinositide 3-kinase g; PK/PD, pharmacokinetics/pharmacodynamics; sIL-2R, soluble IL-2
receptor; VAS, visual analog scale.
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heterogeneity in transcriptomic profile of lesional skin compared
with psoriasis).63FUTURE DEVELOPMENTS
The development of more sophisticated human and computa-
tional models of AD that integrate large-scale clinical and
‘‘omics’’ data offer the potential for a deeper understanding of
disease endotypes, molecular mechanisms underlying key path-
ogenic events and clinical hallmarks of AD, as well as prediction
of therapeutic outcomes, including comorbidity at the level of an
individual patient. Accepting that, by definition, these models are
based on a reductionist approach, they need to reflect the
complexity of AD pathogenesis, including epidermal barrier
dysfunction, altered penetration of chemicals and allergens,
host/environment interaction, type 2 immunity, and tissue
remodeling. We have illustrated in this review that the mainapproaches available today are in vitromodels, identification and
characterization of human inherited syndromes resembling AD,
in vivo challenges of patients with AD, and in silico models.
Here we speculate how the future of AD research will likely
inform the development of more refined models of AD.
Refinement is likely to depend, at least in part, onmethodological
advances in the field and the additional information generated by
novel approaches. For example, single-cell sequencing has recently
identified novel rare but important immunologic subsets,64 and
intravital photon microscopy has enabled visualization of cell-cell
communication during inflammation.65,66 Application of this
technology to AD is likely to inform the inclusion of distinct
epithelial and immune cell types64 and/or genetically modified
primary human cells.67 Furthermore, small-scale spheroid
organoids can enhance high-throughput approaches in the field.68
Finally, we expect that a technological breakthrough in the
development of 3-dimensional skin models will be facilitated by
cell printers.69,70
FIG 3. Interconnected multilayer networks: the future of human AD modeling. A combination of innovative
in vitro and in silicomodels obtained by a systems biology approach and machine learning algorithms will
be needed to answer clinically relevant questions, such as identification of distinct disease endotypes,
elucidation of molecular pathomechanisms, or prediction of therapeutic response.
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intelligence tools to facilitate physician interpretation in the field
of melanoma diagnostics71 and increasingly as methods to enable
large data set integration. The first examples of disease
classifiers72 and prediction of disease severity from biomarker
sets61,73,74 have recently been published, and we expect this line
of development to continue while ensuring a sufficient level of
validation. We anticipate that refinement of these methods, in
combination with in silico models, can lead to computational
approaches and predictive models applied to diagnostics and
therapeutic stratification.
The descriptive disease ontology of inflammatory skin diseases
will need to be revised by shifting to pathogenesis-oriented
structure75 and, in the future, by better definition of disease
endotypes based on integration of multiomics data, clinical
features, and clinical response to therapy in light of in silico
models as assessed in large-scale and longitudinal cohorts.76
These advances are likely to inform the development of many
of the current models.
However, to achieve a substantial breakthrough, we expect that
different approaches will need to be combined, integrated,
standardized, and performed at larger scale (Fig 3). For example,
observations made in rare human disease variants or through
specific challenge models in patients with AD can be validated
in vitro and mapped to disease signatures in silico. Validation of
functional hypotheses will increasingly depend on
cross-referencing of data derived from clinical samples with
outputs from in vitro models. Integration of clinical, biomarker,
pharmacokinetic and pharmacodynamic (topical and/or
systemic), and clinical outcome data will inform therapydevelopment and precision medicine. Notably, all of our models
depend on how precisely a particular question is asked and the
quality of the clinical input, including the clinical metadata and
integration with ‘‘omics’’ data derived from clinical samples.
Finally, advanced statistical and machine learning analysis
combined with in silico predictive modeling will be required to
integrate information throughout all described layers and data
sets to elucidate underlying mechanisms (and endotypes), further
highlighting the importance of data standardization and scientific
networking.
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